12:00 AM
 | 
Jan 16, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Amigal migalastat: Preliminary Phase II data

Data from the 6 patients in the open-label Phase II Study 013 showed a positive drug-drug interaction between 150 mg Amigal and Fabrazyme agalsidase beta. In 4 patients receiving 0.5 mg/kg Fabrazyme every 2 weeks, co-administration with Amigal led to a 2- to 4.2-fold increase in plasma active enzyme as measured by total area under the curve (AUC) vs. ERT alone. In skin biopsies from 3...

Read the full 320 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >